利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.024 秒)

    CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS
    4.
    发明公开
    CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS 审中-公开
    KREBSBEHANDLUNGEN UNTER VERWENDUNG VON KOMBINATIONEN AUS PI3K / AKT-SIGNALWEG- UND ERK-HEMMERN

    公开(公告)号：EP3082957A1

    公开(公告)日：2016-10-26

    申请号：EP14871139.3

    申请日：2014-12-19

    申请人： Biomed Valley Discoveries, Inc.

    发明人： SAHA, Saurabh ,  WELSCH, Dean ,  DECRESCENZO, Gary ,  ROIX, Jeffrey James

    IPC分类号： A61P35/00

    CPC分类号： A61K31/4439 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  A61K2300/00

    摘要： The present invention provides, inter alia, methods, kits, and compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. This method includes administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is an inhibitor of the PI3K/Akt pathway or a pharmaceutically acceptable salt thereof. Also provided are methods of treating or ameliorating the effects of a subject with cancer in which the subject has a somatic KRAS and a somatic PIK3CA mutation or in which the cancer is refractory to a therapy selected from RAF inhibitor therapy, MEK inhibitor therapy, and RAF and MEK inhibitor therapy.

    摘要翻译： 本发明尤其提供用于治疗或改善有需要的受试者中癌症的作用的方法，试剂盒和组合物。 该方法包括向受试者施用有效量的（i）第一抗癌剂，其为BVD-523或其药学上可接受的盐，和（ii）第二种抗癌剂，其为PI3K的抑制剂 / Akt途径或其药学上可接受的盐。 还提供了治疗或改善患有癌症的受试者具有体细胞KRAS和体细胞PIK3CA突变或其中癌症对于选自RAF抑制剂治疗，MEK抑制剂治疗和RAF的治疗难治的方法 和MEK抑制剂治疗。

    CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS
    5.
    发明公开
    CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS 审中-公开
    KREBSBEHANDLUNG MITTELS KOMBINATIONEN AUS ERK- UND RAF-HEMMERN

    公开(公告)号：EP3082800A2

    公开(公告)日：2016-10-26

    申请号：EP14872061.8

    申请日：2014-12-19

    申请人： Biomed Valley Discoveries, Inc.

    发明人： SAHA, Saurabh ,  WELSCH, Dean ,  DECRESCENZO, Gary ,  ROIX, Jeffrey James

    IPC分类号： A61K31/395 ,  A61K39/395

    CPC分类号： A61K31/4439 ,  A61K31/428 ,  A61K31/437 ,  A61K31/44 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/555 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention provides,
    inter alia , methods of treating or ameliorating the effects of a cancer in a subject. The methods include administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a type 1 RAF inhibitor (such as dabrafenib) or another RAF inhibitor (such as regorafenib) or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Also provided are pharmaceutical compositions and kits for treating or ameliorating the effects of a cancer in a subject.

    摘要翻译： 本发明尤其提供了治疗或改善受试者中癌症的作用的方法。 所述方法包括向受试者施用有效量的（i）第一种抗癌剂，其为BVD-523或其药学上可接受的盐，和（ii）第二种抗癌剂，其为第1型RAF抑制剂 （如dabrafenib）或另一种RAF抑制剂（如罗非非非）或其药学上可接受的盐，以治疗或改善癌症的作用。 还提供了用于治疗或改善受试者中癌症的作用的药物组合物和试剂盒。

    CANCER TREATMENTS USING COMBINATIONS OF MEK TYPE I AND ERK INHIBITORS
    8.
    发明公开
    CANCER TREATMENTS USING COMBINATIONS OF MEK TYPE I AND ERK INHIBITORS 审中-公开
    KREBSBEHANDLUNGEN UNTER VERWENDUNG VON KOMBINATIONEN AUS TYP-1-MEK- UND -ERK-HEMMERN

    公开(公告)号：EP3082422A2

    公开(公告)日：2016-10-26

    申请号：EP14871339.9

    申请日：2014-12-19

    申请人： Biomed Valley Discoveries, Inc.

    发明人： SAHA, Saurabh ,  DECRESCENZO, Gary ,  ROIX, Jeffrey James

    IPC分类号： A01N43/40 ,  C07D401/00

    CPC分类号： A61K31/4439 ,  A61K31/365 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention provides,
    inter alia , methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method comprises administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a type 1 MEK inhibitor or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Additional methods for effecting cancer cell death are also provided.

    摘要翻译： 本发明尤其提供用于治疗或改善有需要的受试者中癌症的作用的方法，试剂盒和药物组合物。 该方法包括向受试者施用有效量的（i）第一抗癌剂，其为BVD-523或其药学上可接受的盐，和（ii）第二种抗癌剂，其为1型MEK抑制剂 或其药学上可接受的盐，以治疗或改善癌症的作用。 还提供了用于实现癌细胞死亡的其它方法。